Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LBI-101
- Development stage
- Unknown
- Lead developer
- Longevity Biomedical
- Modality
- Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Injection
01
Overview
LBI-101 is an off-the-shelf allogenic tissue biomaterial developed as an injectable product for the permanent reconstruction of soft tissue affected by aging, traumatic injuries, and surgical procedures. The product is designed to stimulate tissue repair and regeneration. Clinical studies have demonstrated initial safety, biocompatibility, and new tissue formation without the scarring typically associated with other injection-based therapies. LBI-101 is currently being investigated in a Phase 2 clinical study for soft-tissue reconstruction[3][6][1].
Beyond the preview
Go deeper on LBI-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LBI-101.